
Kutsu Desentum Oy:n varsinaiseen yhtiökokoukseen 2022 / Summons to the 2022 Annual General Meeting of Desentum Oy
Desentum Oy:n varsinainen yhtiökokous pidetään 22.6.2022 / The AGM of Desentum Oy is to be held on Jun 22nd, 2022.
Read more »Imagine a world where every child can play outside in the spring without a runny nose. Imagine a world where asthma is as easy to conquer as the flu. Imagine a world where warnings about peanut residue on chocolate bars are vain. We believe this world can exist.
Desentum Oy:n varsinainen yhtiökokous pidetään 22.6.2022 / The AGM of Desentum Oy is to be held on Jun 22nd, 2022.
Read more »Desentum Oy completed a First-in-Human clinical study last year with an immunotherapeutic hypoallergen targeted for treating birch pollen allergy. In January 2022, the company raised 8 million euros...
Read more »Today, Desentum announced positive First-in-Human clinical data of DM-101, its lead candidate for treatment of birch pollen allergy. DM-101 was found to be safe and well tolerated in a dose regimen...
Read more »Desentum is a clinical-stage biopharmaceutical company developing novel types of allergen immunotherapy products that actually change the way the immune system reacts to allergens. We have a unique technology that can lead to major improvements in the future treatment of allergies.
Our immunotherapeutic products consist of recombinant allergens specifically modified to suppress the histamine release during the desensitization process. They can significantly reduce the risk of serious adverse effects and the time required for immunotherapy.
16